news-med.jpg

Henning Steinhagen appointed as Executive Vice President Drug Discovery and Development and Site-Head Verona

henning.jpgWe are pleased to announce the appointment of Henning Steinhagen, PhD, as Executive Vice President Drug Discovery and Development, and Site-Head Verona, completing Aptuit’s executive leadership team.

Henning joins us from Grünenthal, where he was Senior Vice President, and Head of Global Drug Discovery. His accomplishments included discovery successes in multiple therapeutic areas and establishing multiple research partnerships. 

Prior to his time at Grünenthal, Henning spent seven years at Sanofi-Aventis in positions of increasing responsibility in medicinal chemistry. Before that he was in the medicinal chemistry group at Bayer.

As well as his successful track record in R&D Henning has held senior academic appointments at RWTH University Aachen, Germany, and Trinity College Dublin, Ireland. He holds a PhD in Organic Chemistry and a minor degree in Molecular Genetics. His experience also includes a post-doctoral fellowship at Harvard University, USA

Henning commented, “I am delighted to be joining Aptuit Verona and becoming part of this incredibly talented team.  Verona’s strong track record and legacy of being the world’s premier integrated Research and Development partner research organization is well deserved. Verona is poised for continued growth and success; I look forward to helping our valued customers achieve successful outcomes through the quality and speed of our integrated research and development capabilities.”

Read the full press release

 

Topics: New appointments